Baird Financial Group
IMDX

Baird Financial Group’s Insight Molecular Diagnostics IMDX Stock Holding History

Baird Financial Group’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-504
Closed -$21K – 1538
2019
Q3 		$21K Buy
+504
New +$19.8K ﹤0.01% 1500

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Baird Financial Group's IMDX Position: Q4 2019 in Review

Baird Financial Group sold out of Insight Molecular Diagnostics (IMDX) in Q4 2019, closing a stake of 504 shares — an estimated $21K sold.

Baird Financial Group first reported a position in IMDX in Q3 2019 and held it in 1 quarter. The position peaked at $21K in Q3 2019. 56 funds tracked by Wall St. Rank hold IMDX as of Q4 2019.

  • Baird Financial Group reported no remaining Insight Molecular Diagnostics position as of Q4 2019 after selling out during the quarter.
  • Baird Financial Group sold 504 Insight Molecular Diagnostics shares in Q4 2019, an estimated $21K.
  • Baird Financial Group first reported a position in Insight Molecular Diagnostics in Q3 2019 and held it in 1 quarter.
  • Baird Financial Group's Insight Molecular Diagnostics position peaked at $21K in Q3 2019.
  • 56 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2019.

Based on Baird Financial Group's 13F filing for Q4 2019, filed 14 Feb 2020.